Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.38 |
| ▸ | THRA | P10827 | 6/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809710 | 0.81 | ITGB3 (0.38) | MEN1KMT2A | |
| SCHEMBL6806028 | 0.80 | MAPT (0.38) | THRBKDM4EALDH1A1 | |
| SCHEMBL6803905 | 0.71 | SMN1; SMN2 (0.41) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6800487 | 0.70 | HPGD (0.38) | CYP1A2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6804104 | 0.68 | ITGB3 (0.44) | — | |
| SCHEMBL13062424 | 0.66 | THRA (0.48) | THRBTHRAALDH1A1 | |
| SCHEMBL19510751 | 0.66 | CYP1A2 (0.45) | THRBTHRACYP1A2MEN1KMT2A | |
| SCHEMBL13243149 | 0.65 | THRA (0.38) | THRBTHRACYP1A2SMN1; SMN2 | |
| SCHEMBL6809716 | 0.64 | ESR1 (0.47) | MEN1KMT2A | |
| SCHEMBL6806054 | 0.63 | CA12 (0.39) | CYP1A2MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | THRB 688/4885THRA 1179/4885ICMT 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.